BofA/Merrill Lynch Downgrades Catalent (CTLT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Catalent, Inc. Reports Third Quarter 2016 Results
May 4, 2016 4:17 PM EDTRevenue decreased 2% as reported and increased 2% in constant currency to $438.0 million from third quarter 2015 Adjusted Net Income(1) totaled $25.0 million, or $0.20 per diluted share Full resolution of Beinheim facility license suspension; license reinstated April 28th, 2016
SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the third quarter of fiscal year 2016, which... More
